SAMANTHA DELAHANTY: Open Payments
NPI 1124750492 · LOWELL, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,087 in 197 payments from 19 companies in 2025. Trend: 2023 $56 · 2024 $1,576 · 2025 $4,087
Food & beverage: $4,010Education: $77
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 36 | $652 |
| Janssen Biotech, Inc. | 22 | $562 |
| Takeda Pharmaceuticals U.S.A., Inc. | 25 | $513 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 35 | $416 |
| Gilead Sciences, Inc. | 15 | $397 |
| Ardelyx, Inc. | 13 | $283 |
| PFIZER INC. | 13 | $234 |
| Phathom Pharmaceuticals, Inc. | 8 | $183 |
| Madrigal Pharmaceuticals | 4 | $157 |
| Ipsen Biopharmaceuticals, Inc | 5 | $130 |
Products named: TREMFYA, ENTYVIO, XIFAXAN, IBSRELA, RINVOQ, DUPIXENT, VOQUEZNA, XELJANZ.
Industry payments across MA — which companies pay providers there.
